Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeks Antidepressant treatment effects observed within one week and
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
– Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events – – Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 – This news release constitutes a “designated news release” for the
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC Proven leader in late-stage clinical development,
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Helus Pharma builds on the strong foundation originally created as Cybin Inc. , reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
TORONTO –(BUSINESS WIRE)–Dec. 30, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
TORONTO –(BUSINESS WIRE)–Dec. 18, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily
Cybin to Participate in the Jefferies Global Healthcare Conference in London
TORONTO –(BUSINESS WIRE)–Nov. 12, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
– Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 – TORONTO –(BUSINESS WIRE)–Nov. 6, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TORONTO –(BUSINESS WIRE)–Nov. 5, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
– Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 – TORONTO –(BUSINESS WIRE)–Nov. 3, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental